{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:06:08Z","timestamp":1773788768888,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102472","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T11:20:20Z","timestamp":1598700020000},"page":"102472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirreza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Navardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-0911","authenticated-orcid":false,"given":"Abdorreza","family":"Naser Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102472_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30195-X","article-title":"Real estimates of mortality following COVID-19 infection","author":"Baud","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2020.102472_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102472_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102276","article-title":"Characteristics of COVID-19 disease in multiple sclerosis patients","author":"Barzegar","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102472_bib0003","first-page":"97","volume":"96","author":"Betaseron","year":"1998","journal-title":"Dev. Biol. Stand."},{"issue":"Suppl 201","key":"10.1016\/j.msard.2020.102472_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ane.12835","article-title":"Infections in patients with multiple sclerosis: implications for disease-modifying therapy","volume":"136","author":"Celius","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2020.102472_bib0023","doi-asserted-by":"crossref","unstructured":"Chaudhry F., Bulka H., Rathnam A.S., et\u00a0al. COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection. MedRxiv doi: https:\/\/doi.org\/10.1101\/2020.05.27.20114827.","DOI":"10.1101\/2020.05.27.20114827"},{"issue":"5","key":"10.1016\/j.msard.2020.102472_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000787","article-title":"Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders","volume":"7","author":"Fan","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2020.102472_bib0001","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2020.102472_bib0034","doi-asserted-by":"crossref","unstructured":"Gallais F., Velay A., Wendling M.J., et\u00a0al. Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion. MedRXiv. doi: https:\/\/doi.org\/10.1101\/2020.06.21.20132449.","DOI":"10.1101\/2020.06.21.20132449"},{"key":"10.1016\/j.msard.2020.102472_bib0006","unstructured":"GavinGiovannoni, et\u00a0al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult. Scler. Relat. Disord., 10.1016\/j.msard.2020.102073."},{"key":"10.1016\/j.msard.2020.102472_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102222","article-title":"Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic","volume":"43","author":"Ghajarzadeh","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2020.102472_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.msard.2020.102472_bib0024","article-title":"COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series [published online ahead of print, 2020 May 16]","volume":"42","author":"Hughes","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102472_bib0018","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s13063-020-04382-3","article-title":"Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Irvani","year":"2020","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.msard.2020.102472_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.neurol.2018.04.004","article-title":"Induction or escalation therapy for patients with multiple sclerosis?","volume":"174","author":"Le Page","year":"2018","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2020.102472_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102472_bib0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102472_bib0010","article-title":"Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain","volume":"43","author":"Montero-Escribano","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10076","key":"10.1016\/j.msard.2020.102472_bib0002","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","article-title":"Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function","volume":"389","author":"Ontaneda","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2020.102472_bib0022","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102472_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102472_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102193","article-title":"Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): a report from Iran","volume":"42","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102472_bib0033","doi-asserted-by":"crossref","unstructured":"Sekine T., Perez-Potti A., Rivera-Ballesteros O., et\u00a0al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. BioRXiv https:\/\/doi.org\/10.1101\/2020.06.29.174888.","DOI":"10.1101\/2020.06.29.174888"},{"issue":"3\u2013S","key":"10.1016\/j.msard.2020.102472_bib0013","first-page":"175","article-title":"COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population","volume":"91","author":"Signorelli","year":"2020","journal-title":"Acta Biomed."},{"issue":"6","key":"10.1016\/j.msard.2020.102472_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis","volume":"19","author":"Sormani","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102472_bib0027","doi-asserted-by":"crossref","unstructured":"Sormani M.P., De Rossi Nicola, Schiavetti I et\u00a0al. Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN 2020: http:\/\/dx.doi.org\/10.2139\/ssrn.3631244.","DOI":"10.2139\/ssrn.3631244"},{"key":"10.1016\/j.msard.2020.102472_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30246-2","article-title":"Estimating case fatality rates of COVID-19","author":"Spychalski","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2020.102472_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102201","article-title":"Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab","volume":"42","author":"Suwanwongse","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2020.102472_bib0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2020.102472_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102139","article-title":"Rethinking high-risk groups in COVID-19","volume":"42","author":"Vishnevetsky","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2020.102472_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.msard.2020.102472_bib0014","article-title":"A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence","volume":"105948","author":"Wang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"10","key":"10.1016\/j.msard.2020.102472_bib0005","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2020.102472_bib0020","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00415-020-09822-3","article-title":"Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19\/SARS-CoV-2","volume":"267","author":"Willis","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102472_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: a review","volume":"215","author":"Yuki","year":"2020","journal-title":"Clin. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:53:53Z","timestamp":1761900833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"alternative-id":["S2211034820305472"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102472","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102472"}}